368 related articles for article (PubMed ID: 26343314)
1. Comparison of cardiac events associated with liposomal doxorubicin, epirubicin and doxorubicin in breast cancer: a Bayesian network meta-analysis.
Yamaguchi N; Fujii T; Aoi S; Kozuch PS; Hortobagyi GN; Blum RH
Eur J Cancer; 2015 Nov; 51(16):2314-20. PubMed ID: 26343314
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological interventions for preventing anthracycline-induced clinical and subclinical cardiotoxicity: A network meta-analysis of metastatic breast cancer.
Ghasemi K; Vaseghi G; Mansourian M
J Oncol Pharm Pract; 2021 Mar; 27(2):414-427. PubMed ID: 33081570
[TBL] [Abstract][Full Text] [Related]
3. Different anthracycline derivates for reducing cardiotoxicity in cancer patients.
van Dalen EC; Michiels EM; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2010 Mar; (3):CD005006. PubMed ID: 20238335
[TBL] [Abstract][Full Text] [Related]
4. Different anthracycline derivates for reducing cardiotoxicity in cancer patients.
van Dalen EC; Michiels EM; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2006 Oct; (4):CD005006. PubMed ID: 17054231
[TBL] [Abstract][Full Text] [Related]
5. Different anthracycline derivates for reducing cardiotoxicity in cancer patients.
van Dalen EC; Michiels EM; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2010 May; 2010(5):CD005006. PubMed ID: 20464735
[TBL] [Abstract][Full Text] [Related]
6. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
7. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials.
Smith LA; Cornelius VR; Plummer CJ; Levitt G; Verrill M; Canney P; Jones A
BMC Cancer; 2010 Jun; 10():337. PubMed ID: 20587042
[TBL] [Abstract][Full Text] [Related]
8. Comparisons of Cardiotoxicity and Efficacy of Anthracycline-Based Therapies in Breast Cancer: A Network Meta-Analysis of Randomized Clinical Trials.
Mao Z; Shen K; Zhu L; Xu M; Yu F; Xue D; Li H; Xue C
Oncol Res Treat; 2019; 42(7-8):405-413. PubMed ID: 31104059
[TBL] [Abstract][Full Text] [Related]
9. Effects of Doxorubicin, Epirubicin, and Liposomal Doxorubicin (Anthracycline) on cardiac function in patients with osteosarcoma and their influencing factors.
Ding S; Xiong S; Wang X; Zhang C; Chen S; Sun M; Wu C; Zhang X; Wang M; Wang J; Shang X
Clin Transl Oncol; 2024 Jun; 26(6):1459-1466. PubMed ID: 38329609
[TBL] [Abstract][Full Text] [Related]
10. Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy.
van Dalen EC; van der Pal HJ; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2009 Oct; (4):CD005008. PubMed ID: 19821337
[TBL] [Abstract][Full Text] [Related]
11. Different dosage schedules for reducing cardiotoxicity in people with cancer receiving anthracycline chemotherapy.
van Dalen EC; van der Pal HJ; Kremer LC
Cochrane Database Syst Rev; 2016 Mar; 3(3):CD005008. PubMed ID: 26938118
[TBL] [Abstract][Full Text] [Related]
12. Epirubicin versus doxorubicin: which is the anthracycline of choice for the treatment of breast cancer?
Kaklamani VG; Gradishar WJ
Clin Breast Cancer; 2003 Apr; 4 Suppl 1():S26-33. PubMed ID: 12756076
[TBL] [Abstract][Full Text] [Related]
13. Liposomal doxorubicin attenuates cardiotoxicity via induction of interferon-related DNA damage resistance.
Gyöngyösi M; Lukovic D; Zlabinger K; Spannbauer A; Gugerell A; Pavo N; Traxler D; Pils D; Maurer G; Jakab A; Riesenhuber M; Pircher A; Winkler J; Bergler-Klein J
Cardiovasc Res; 2020 Apr; 116(5):970-982. PubMed ID: 31346605
[TBL] [Abstract][Full Text] [Related]
14. Cardiotoxicity of a non-pegylated liposomal doxorubicin-based regimen versus an epirubicin-based regimen for breast cancer: the LITE (Liposomal doxorubicin-Investigational chemotherapy-Tissue Doppler imaging Evaluation) randomized pilot study.
Lotrionte M; Palazzoni G; Abbate A; De Marco E; Mezzaroma E; Di Persio S; Frati G; Loperfido F; Biondi-Zoccai G
Int J Cardiol; 2013 Aug; 167(3):1055-7. PubMed ID: 23174173
[No Abstract] [Full Text] [Related]
15. Evaluation of cardiotoxicity of anthracycline-containing chemotherapy regimens in patients with bone and soft tissue sarcomas: A study of the FDA adverse event reporting system joint single-center real-world experience.
Mo Z; Deng Y; Bao Y; Liu J; Jiang Y
Cancer Med; 2023 Dec; 12(24):21709-21724. PubMed ID: 38054208
[TBL] [Abstract][Full Text] [Related]
16. Liposomal doxorubicin in breast cancer: new preparation. Much ado about nothing.
Prescrire Int; 2003 Jun; 12(65):93-5. PubMed ID: 12825572
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Cardiotoxicity of Liposomal Doxorubicin-Based Chemotherapy in Advanced Breast Cancer: A Meta-Analysis of Ten Randomized Controlled Trials.
Xing M; Yan F; Yu S; Shen P
PLoS One; 2015; 10(7):e0133569. PubMed ID: 26204517
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and toxicity of pegylated liposomal doxorubicin-based chemotherapy in early-stage breast cancer: a multicenter retrospective case-control study.
Yang FO; Hsu NC; Moi SH; Lu YC; Hsieh CM; Chang KJ; Chen DR; Tu CW; Wang HC; Hou MF
Asia Pac J Clin Oncol; 2018 Jun; 14(3):198-203. PubMed ID: 29045014
[TBL] [Abstract][Full Text] [Related]
19. Epirubicin in combination with the taxanes.
Trudeau M; Pagani O
Semin Oncol; 2001 Aug; 28(4 Suppl 12):41-50. PubMed ID: 11552229
[TBL] [Abstract][Full Text] [Related]
20. HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer.
Miller K; Cortes J; Hurvitz SA; Krop IE; Tripathy D; Verma S; Riahi K; Reynolds JG; Wickham TJ; Molnar I; Yardley DA
BMC Cancer; 2016 Jun; 16():352. PubMed ID: 27259714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
